[1] 郭宏岗, 沈建良.原发免疫性血小板减少症发病机制的研究进展[J].山东医药, 2016, 56(11):96-99. [2] Zufferey A, Kapur R, Semple J.Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)[J].J Clin Med, 2017, 6(2):16. [3] 温顺祝, 傅红春, 李晓明.原发性免疫性血小板减少症研究进展[J].西南国防医药, 2016, 26(7):821-823. [4] Min Y N, Wang C Y, Li X X, et al.Participation of B-cell-activating factor receptors in the pathogenesis of immune thrombocytopenia[J].J Thromb Haemost, 2016, 14(3):559-571. [5] El-Rashedi F H, El-Hawy M A, Helwa M A, et al.Study of CD4+, CD8+, and natural killer cells(CD16+, CD56+) in children with immune thrombocytopenic Purpura[J].Hematol Stem Cell Ther, 2017, 10(1):8-14. [6] Takahashi N, Saitoh T, Gotoh N, et al.The cytokine polymorphisms affecting Th1/Th2 increase the susceptibility to, and severity of, chronic ITP[J].BMC Immunol, 2017, 18(1):1-11. [7] Dreymueller D, Goetzenich A, Emontzpohl C, et al.The perioperative time course and clinical significance of the chemokine CXCL16 in patients undergoing cardiac surgery[J].J Cell Mol Med, 2016, 20(1):104-115. [8] Hao Y T, Li Y, Li H Y, et al.Increased plasma sCXCL16 levels may have a relationship with Th1/Th2 imbalance in primary immune thrombocytopenia[J].Cytokine, 2017, 99:124-131. [9] Tang YY, Wei YF, Ye Z M, et al.Th1, Th17, CXCL16 and homocysteine elevated after intracranial and cervical stent implantation[J].Int J Neurosci, 2017, 127(8):701-708. [10] Ke CW, Ren YC, Lv L, et al.Association between CXCL16/CXCR6 expression and the clinicopathological features of patients with non-small cell lung cancer[J].Oncol Lett, 2017, 13(6):4661-4668. [11] 中华医学会血液学分会止血与血栓学组.成人原发免疫性血小板减少症诊断与治疗中国专家共识(2016年版)[J].中华血液学杂志, 2016, 37(2):89-93. [12] 陈玙, 王梅芳, 程芳芳, 等.老年原发免疫性血小板减少症患者临床特征及预后分析[J].首都医科大学学报, 2018, 39(2):277-281. [13] 郭莹, 瞿文, 王一浩, 等.共刺激信号分子对免疫性血小板减少症患者B淋巴细胞免疫功能的影响[J].中国实验血液学杂志, 2016, 24(4):1110-1115. [14] 陈燕, 邢宏运, 李晓明, 等.Fas/FasL在原发免疫性血小板减少症发病机制中的作用研究[J].重庆医学, 2016, 45(20):2795-2797. [15] Gruber H, Marrero E, Ingram J, et al.The chemokine, CXCL16, and its receptor, CXCR6, are constitutively expressed in human annulus fibrosus and expression of CXCL16 is up-regulated by exposure to IL-1ß in vitro[J].Biotech Histochem, 2017, 92(1):7-14. [16] 戴昕, 李文倩, 李建平, 等.血浆HMGB1、IFN-γ、IL-4和CD4~+T细胞表面TLR4的表达在免疫性血小板减少症患者中的意义[J].中国实验血液学杂志, 2016, 24(6):1837-1841. [17] Takiguchi G, Nishita M, Kurita K, et al.Wnt5a-Ror2 signaling in mesenchymal stem cells promotes proliferation of gastric cancer cells by activating CXCL16-CXCR6 axis[J].Cancer Sci, 2016, 107(3):290-297. [18] Cho SW, Kim YA, Sun H J, et al.CXCL16 signaling mediated macrophage effects on tumor invasion of papillary thyroid carcinoma[J].Endocr-Relat Cancer, 2016, 23(2):113-124. [19] Wu JB, He Y, Luo YN, et al.MiR-145-5p inhibits proliferation and inflammatory responses of RMC through regulating AKT/GSK pathway by targeting CXCL16[J].J Cell Physiol, 2018, 233(4):3648-3659. [20] Chapin J, Lee CS, Zhang HY, et al.Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia[J].Am J Hematol, 2016, 91(9):907-911. |